CDKN2A and pancreatic neoplasm: In a prospective phase II clinical trial known as TAPUR, where 12 patients with pancreatic cancer and a variant mutation in the CDKN2A gene received Palbociclib monotherapy, no objective response was confirmed after 16 weeks.